Camurus: Eli Lilly Exercises Collaboration Option - Redeye
This afternoon, Eli Lilly exercised its option to include amylin receptor agonists in the collaboration and license agreement entered in June 2025. This triggers an USD5m payment to Camurus.
ANNONS
This afternoon, Eli Lilly exercised its option to include amylin receptor agonists in the collaboration and license agreement entered in June 2025. This triggers an USD5m payment to Camurus.
